Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.

ABSTRACT:

Aims

Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce several cardiovascular risk factors, including plasma glucose, blood pressure, albuminuria and body weight. Long-term treatment lowers risks of cardiovascular and renal events. The objective of this post hoc analysis was to determine the effects of canagliflozin treatment versus placebo on clinical outcomes in relation to body mass index (BMI).

Materials and methods

The CANVAS Program randomized 10 142 participants with type 2 diabetes to canagliflozin or placebo. These analyses tested the consistency of canagliflozin treatment effects across BMI levels for cardiovascular, renal, safety and body weight outcomes in three groups defined by baseline BMI: <25, 25-<30 and ≥30 kg/m² .

Results

In total

SUBMITTER: Ohkuma T 

PROVIDER: S-EPMC7078821 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature